Exelon Side Effects
Generic name: rivastigmine
Note: This document contains side effect information about rivastigmine. Some of the dosage forms listed on this page may not apply to the brand name Exelon.
Some side effects of Exelon may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to rivastigmine: oral capsule, oral solution
Other dosage forms:
Along with its needed effects, rivastigmine (the active ingredient contained in Exelon) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur while taking rivastigmine:More common
- loss of appetite
- loss of strength
- nausea and vomiting
- weight loss
- High blood pressure
- convulsions (seizures)
- trembling and shaking of hands and fingers
- trouble in urinating
- fast weak pulse
- greatly increased sweating
- greatly increased watering of mouth
- irregular breathing
- increasing muscle weakness
- large pupils
- low blood pressure
- slow heartbeat
- vomiting (severe)
Some side effects of rivastigmine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Abdominal or stomach pain or cramping
- bloated full feeling
- mental depression
- seeing, hearing, or feeling things that are not there
- trouble in sleeping
- General feeling of discomfort or illness
- increased sweating
- runny nose
For Healthcare Professionals
Applies to rivastigmine: oral capsule, oral solution, transdermal film extended release
Gastrointestinal effects including nausea (47%), vomiting (31%), diarrhea (19%), anorexia (17%), abdominal pain (13%), dyspepsia (9%), constipation (5%), flatulence (4%), and eructation (2%) have been reported. There has also been one postmarketing report of severe vomiting with esophageal rupture following inappropriate reinitiation of treatment. Postmarketing reports have included duodenal ulcers.
When treatment is interrupted for longer than several days, treatment must be reinitiated with the lowest daily dose to reduce the possibility of severe vomiting and its potentially serious sequelae.
Nervous system side effects including dizziness (21%), headache (17%), somnolence (5%), tremor (4%), increased sweating (4%), and syncope (3%) have been reported. Postmarketing reports have included confusion.
General side effects including accidental trauma (10%), fatigue (9%), asthenia (6%), malaise (5%), influenza-like symptoms (3%), and decreased weight (3%) have been reported.
Psychiatric side effects including insomnia (9%), confusion (8%), depression (6%), anxiety (5%), hallucination (4%), and aggressive reaction (3%) have been reported.
Dermatologic side effects including Stevens-Johnson syndrome have been reported. A case of erythematous macropapular eruption due to rivastigmine (the active ingredient contained in Exelon) therapy has also been reported. Postmarketing side effects have included reports of disseminated cutaneous hypersensitivity reactions.
Genitourinary side effects including urinary tract infection (7%) have been reported.
Respiratory side effects including rhinitis (4%) have been reported.
Cardiovascular side effects including hypertension (3%) have been reported. A case of complete atrioventricular block has also been reported.
Hepatic side effects have included abnormal liver function tests.
More Exelon resources
- Exelon Prescribing Information (FDA)
- Exelon Consumer Overview
- Exelon Monograph (AHFS DI)
- Exelon MedFacts Consumer Leaflet (Wolters Kluwer)
- Exelon Advanced Consumer (Micromedex) - Includes Dosage Information
- Rivastigmine Prescribing Information (FDA)
- Rivastigmine Professional Patient Advice (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.